# Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05990452/  
OnCo record `nct05990452` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of 9MW2921 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., active and no longer recruiting.

## Summary

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors. ClinicalTrials.gov record last updated 2024-11-21: active not recruiting. Enrollment is planned at 261 participants. Primary completion is estimated at 2026-09-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: 9MW2921. Registered primary measures: Dose Limited Toxicity (DLT); Adverse Events and Serious Adverse Events; ORR.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05990452
- Phase: 1/2
- Setting: Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 261

## Notes

- ClinicalTrials.gov record last updated 2024-11-21: active not recruiting. Enrollment is planned at 261 participants. Primary completion is estimated at 2026-09-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT05990452: https://clinicaltrials.gov/study/NCT05990452

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- companies: [Mabwell (Shanghai) Bioscience](https://onco.cc/companies/mabwell-shanghai-bioscience/)
- drugs: [9MW2921](https://onco.cc/drugs/9mw2921/)

---
JSON: https://onco.cc/api/v1/entities/nct05990452.json